ALS drug trial halted: ARGX-119 fails to show promise
NCT ID NCT06441682
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called ARGX-119 in 60 adults with ALS. The goal was to see if it was safe and could help with muscle function. The trial was stopped early because early results showed it was unlikely to make a meaningful difference. No safety concerns triggered the stop, but the drug did not appear effective enough to continue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARGX-119 (an experimental biologic drug given by IV infusion)
What this could lead to
If it had worked, this could have pointed toward a treatment to slow muscle decline in ALS. However, the study was stopped early because it was unlikely to show a meaningful benefit.
What could go wrong
This trial was stopped early because early data suggested it would not help patients. The drug is still experimental, and even if safe, it may not improve muscle function or slow the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus Universitets Hospital
Aarhus, 8200, Denmark
-
Akademiskt specialistcentrum Karolinska Institutet
Stockholm, 113 61, Sweden
-
Bispebjerg University Hospital
Copenhagen, 2400, Denmark
-
CHU Bretonneau
Tours, 37000, France
-
Hôpital La Pitié Salpêtrière
Paris, 75013, France
-
Kaye Edmonton Clinic
Edmonton, 11400, Canada
-
Montreal Neurological Institute and Hospital
Montreal, H3A 2B4, Canada
-
UMC Utrecht
Utrecht, 3584 CX, Netherlands
-
UZ Leuven
Leuven, 3000, Belgium